Skip to main content
. Author manuscript; available in PMC: 2014 Mar 21.
Published in final edited form as: J Neurochem. 2012 Aug 23;123(2):288–297. doi: 10.1111/j.1471-4159.2012.07875.x

Figure 5. Repeated METH administrations resulted in persistent loss of striatal DAT immunoreactivity.

Figure 5

Rats were treated with repeated saline (4 × 1 ml/kg/injection, 2-h intervals, s.c.) or METH (4 × 7.5 mg/kg/injection, 2-h intervals, s.c.) injections and DAT immunoreactivity within synaptosomal membrane and vesicle fractions was determined 7 d later (n = 6 per group). (A) DAT immunoreactivity was reduced within METH-treated fractions as compared to saline-treated control fractions. (B) DAT immunoreactivity was reduced within METH-treated synaptosomal membranes as compared to saline-treated controls. ## Treatment across fractions different than saline-treated fractions (p ≤ 0.01). * Fraction different than comparable saline-treated fraction (p ≤ 0.05). ** Fraction different than comparable saline-treated fraction (p ≤ 0.01). *** Fraction different than comparable saline-treated fraction (p ≤ 0.001). ‘DAT P’ indicates DAT peptide control lane.